NO330223B1 - Fremgangsmate for fremstillingen av perindopril med hoy renhet og intermediater nyttige i syntesen - Google Patents
Fremgangsmate for fremstillingen av perindopril med hoy renhet og intermediater nyttige i syntesen Download PDFInfo
- Publication number
- NO330223B1 NO330223B1 NO20043472A NO20043472A NO330223B1 NO 330223 B1 NO330223 B1 NO 330223B1 NO 20043472 A NO20043472 A NO 20043472A NO 20043472 A NO20043472 A NO 20043472A NO 330223 B1 NO330223 B1 NO 330223B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- formula
- compound according
- benzyl
- organic solvent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 35
- 238000002360 preparation method Methods 0.000 title claims description 9
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title description 25
- 229960002582 perindopril Drugs 0.000 title description 20
- 230000015572 biosynthetic process Effects 0.000 title description 14
- 238000003786 synthesis reaction Methods 0.000 title description 10
- 239000000543 intermediate Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 27
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 239000003960 organic solvent Substances 0.000 claims description 17
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 16
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 239000012535 impurity Substances 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- 238000005917 acylation reaction Methods 0.000 claims description 11
- -1 alkyl chloroformates Chemical class 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 230000010933 acylation Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 6
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 4
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 claims description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- 150000003512 tertiary amines Chemical class 0.000 claims 2
- 102000006835 Lamins Human genes 0.000 claims 1
- 108010047294 Lamins Proteins 0.000 claims 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical class OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 claims 1
- 210000005053 lamin Anatomy 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- CQYBNXGHMBNGCG-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indol-1-ium-2-carboxylate Chemical group C1CCCC2NC(C(=O)O)CC21 CQYBNXGHMBNGCG-UHFFFAOYSA-N 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QPAOQVAYDANIBL-RGURZIINSA-N (2s)-2-[ethoxycarbonyl(2-ethoxycarbonylbutyl)amino]propanoic acid Chemical compound CCOC(=O)C(CC)CN([C@@H](C)C(O)=O)C(=O)OCC QPAOQVAYDANIBL-RGURZIINSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CJEJWJUDCBIMPG-JAMMHHFISA-N (2s)-2-(2-ethoxycarbonylbutylamino)propanoic acid Chemical compound CCOC(=O)C(CC)CN[C@@H](C)C(O)=O CJEJWJUDCBIMPG-JAMMHHFISA-N 0.000 description 4
- OAYXQRRYMGGBJM-IENPIDJESA-N (2s)-2-[2-ethoxycarbonylbutyl(methoxycarbonyl)amino]propanoic acid Chemical compound CCOC(=O)C(CC)CN([C@@H](C)C(O)=O)C(=O)OC OAYXQRRYMGGBJM-IENPIDJESA-N 0.000 description 4
- PQYVQRGHCJSNFT-CFMCSPIPSA-N (2s)-2-[2-ethoxycarbonylbutyl(phenylmethoxycarbonyl)amino]propanoic acid Chemical compound CCOC(=O)C(CC)CN([C@@H](C)C(O)=O)C(=O)OCC1=CC=CC=C1 PQYVQRGHCJSNFT-CFMCSPIPSA-N 0.000 description 4
- HAZWSVJWBWOGLI-VUWPPUDQSA-N (2s)-2-[2-ethoxycarbonylbutyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound CCOC(=O)C(CC)CN([C@@H](C)C(O)=O)C(=O)OC(C)(C)C HAZWSVJWBWOGLI-VUWPPUDQSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000006243 carbonyl protecting group Chemical group 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02290206A EP1333026B1 (en) | 2002-01-30 | 2002-01-30 | Process for the preparation of high purity perindopril and intermediates useful in the synthesis |
| PCT/IB2003/000691 WO2003064388A2 (en) | 2002-01-30 | 2003-01-29 | Process for the preparation of high purity perindopril and intermediates useful in the synthesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20043472L NO20043472L (no) | 2004-08-20 |
| NO330223B1 true NO330223B1 (no) | 2011-03-07 |
Family
ID=8185713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043472A NO330223B1 (no) | 2002-01-30 | 2004-08-20 | Fremgangsmate for fremstillingen av perindopril med hoy renhet og intermediater nyttige i syntesen |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US7326794B2 (sr) |
| EP (1) | EP1333026B1 (sr) |
| JP (1) | JP4171423B2 (sr) |
| KR (1) | KR100673701B1 (sr) |
| CN (1) | CN1300111C (sr) |
| AP (1) | AP1741A (sr) |
| AR (1) | AR038340A1 (sr) |
| AT (1) | ATE365714T1 (sr) |
| AU (1) | AU2003206055B2 (sr) |
| BG (1) | BG66126B1 (sr) |
| BR (2) | BRPI0307293B1 (sr) |
| CA (1) | CA2474003C (sr) |
| CY (1) | CY1106721T1 (sr) |
| CZ (1) | CZ305892B6 (sr) |
| DE (1) | DE60220877T2 (sr) |
| DK (1) | DK1333026T3 (sr) |
| EA (1) | EA009277B1 (sr) |
| EE (1) | EE05428B1 (sr) |
| ES (1) | ES2289060T3 (sr) |
| GE (1) | GEP20063899B (sr) |
| HK (1) | HK1076101A1 (sr) |
| HR (1) | HRP20040781B8 (sr) |
| HU (1) | HU227591B1 (sr) |
| ME (1) | ME00444B (sr) |
| MX (1) | MXPA04007444A (sr) |
| NO (1) | NO330223B1 (sr) |
| NZ (1) | NZ534168A (sr) |
| OA (1) | OA12759A (sr) |
| PL (1) | PL212354B1 (sr) |
| PT (1) | PT1333026E (sr) |
| RS (1) | RS52465B (sr) |
| SI (1) | SI1333026T1 (sr) |
| SK (1) | SK287866B6 (sr) |
| UA (1) | UA77756C2 (sr) |
| WO (1) | WO2003064388A2 (sr) |
| ZA (1) | ZA200405548B (sr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4677611B2 (ja) * | 2003-10-21 | 2011-04-27 | レ ラボラトワール セルヴィエ | 結晶ペリンドプリルエルブミンの新規な調製方法 |
| SI21704A (en) * | 2004-01-14 | 2005-08-31 | Lek Farmacevtska Druzba Dd | New crystal form of perindopril, procedure of its preparation, pharmaceutical preparations containing this form and their application in treatment of hypertensia |
| LT1729739T (lt) * | 2004-03-29 | 2016-11-10 | Les Laboratoires Servier | Kietos farmacinės kompozicijos gamybos būdas |
| SI21800A (sl) * | 2004-05-14 | 2005-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nov postopek sinteze perindoprila |
| SI21881A (sl) | 2004-10-15 | 2006-04-30 | Diagen, Smartno Pri Ljubljani, D.O.O. | Nove kristalne oblike perindopril erbumin hidratov, postopek za njihovo pripravo in farmacevtske oblike, ki vsebujejo te spojine |
| ES2255872B1 (es) * | 2004-12-31 | 2007-08-16 | Quimica Sintetica, S.A. | Procedimiento para la preparacion de perindopril erbumina. |
| PT1679072E (pt) | 2005-01-06 | 2008-12-22 | Ipca Lab Ltd | Processo para a síntese de derivados de ácido (2s,3as,7as)-1-(s)-alanil-octa-hidro-1h-indole-2-carboxílico e utilização na síntese de perindopril |
| US7710739B2 (en) | 2005-04-28 | 2010-05-04 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and display device |
| WO2006137082A1 (en) * | 2005-06-23 | 2006-12-28 | Ramesh Babu Potluri | Process for industrially viable preparation of perindopril erbumine |
| US20070032661A1 (en) * | 2005-08-03 | 2007-02-08 | Glenmark Pharmaceuticals Limited | Process for the preparation of intermediates of perindopril |
| WO2007020012A1 (en) * | 2005-08-12 | 2007-02-22 | Lek Pharmaceuticals D.D. | A process for the preparation of perindopril erbumine |
| EP1792896A1 (en) * | 2005-12-01 | 2007-06-06 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for the preparation of perindopril and salts thereof |
| EP2044010B1 (en) | 2006-05-12 | 2014-01-08 | EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság | New pharmaceutical intermediates in the synthesis of ace-inihibitors and the use thereof |
| WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
| FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK144769C (da) | 1979-12-06 | 1982-12-13 | Voelund Vaskerimaskiner | Tromlevaskemaskine med varmeveksler |
| US4565819A (en) * | 1979-12-07 | 1986-01-21 | Adir | Substituted imino diacids, their preparation and pharmaceutical compositions which contain them |
| FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| IN156096B (sr) | 1981-03-19 | 1985-05-11 | Usv Pharma Corp | |
| FR2620709B1 (fr) * | 1987-09-17 | 1990-09-07 | Adir | Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese |
| SI9600169A (en) | 1996-05-22 | 1997-12-31 | Krka Tovarna Zdravil | Process for preparation of compounds with ace inhibitory effect |
| FR2807431B1 (fr) | 2000-04-06 | 2002-07-19 | Adir | Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables |
| FR2827860B1 (fr) | 2001-07-24 | 2004-12-10 | Servier Lab | Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril |
| AR036187A1 (es) | 2001-07-24 | 2004-08-18 | Adir | Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario |
-
2002
- 2002-01-30 ES ES02290206T patent/ES2289060T3/es not_active Expired - Lifetime
- 2002-01-30 AT AT02290206T patent/ATE365714T1/de active
- 2002-01-30 EP EP02290206A patent/EP1333026B1/en not_active Expired - Lifetime
- 2002-01-30 PT PT02290206T patent/PT1333026E/pt unknown
- 2002-01-30 SI SI200230586T patent/SI1333026T1/sl unknown
- 2002-01-30 DK DK02290206T patent/DK1333026T3/da active
- 2002-01-30 DE DE60220877T patent/DE60220877T2/de not_active Expired - Lifetime
-
2003
- 2003-01-29 ME MEP-2008-674A patent/ME00444B/me unknown
- 2003-01-29 CN CNB038027143A patent/CN1300111C/zh not_active Expired - Fee Related
- 2003-01-29 NZ NZ534168A patent/NZ534168A/en not_active IP Right Cessation
- 2003-01-29 AU AU2003206055A patent/AU2003206055B2/en not_active Ceased
- 2003-01-29 MX MXPA04007444A patent/MXPA04007444A/es active IP Right Grant
- 2003-01-29 AP APAP/P/2004/003091A patent/AP1741A/en active
- 2003-01-29 SK SK329-2004A patent/SK287866B6/sk not_active IP Right Cessation
- 2003-01-29 EA EA200400929A patent/EA009277B1/ru not_active IP Right Cessation
- 2003-01-29 UA UA20040807143A patent/UA77756C2/uk unknown
- 2003-01-29 OA OA1200400196A patent/OA12759A/en unknown
- 2003-01-29 EE EEP200400107A patent/EE05428B1/xx not_active IP Right Cessation
- 2003-01-29 KR KR1020047011731A patent/KR100673701B1/ko not_active IP Right Cessation
- 2003-01-29 JP JP2003564011A patent/JP4171423B2/ja not_active Expired - Fee Related
- 2003-01-29 WO PCT/IB2003/000691 patent/WO2003064388A2/en active Application Filing
- 2003-01-29 BR BRPI0307293-2A patent/BRPI0307293B1/pt unknown
- 2003-01-29 CZ CZ2004-906A patent/CZ305892B6/cs not_active IP Right Cessation
- 2003-01-29 US US10/503,272 patent/US7326794B2/en not_active Expired - Fee Related
- 2003-01-29 BR BR0307293-2A patent/BR0307293A/pt not_active IP Right Cessation
- 2003-01-29 HU HU0300231A patent/HU227591B1/hu not_active IP Right Cessation
- 2003-01-29 CA CA002474003A patent/CA2474003C/en not_active Expired - Fee Related
- 2003-01-29 GE GE5686A patent/GEP20063899B/en unknown
- 2003-01-29 PL PL358514A patent/PL212354B1/pl unknown
- 2003-01-29 ZA ZA200405548A patent/ZA200405548B/xx unknown
- 2003-01-29 RS YU66704A patent/RS52465B/sr unknown
- 2003-01-30 AR ARP030100263A patent/AR038340A1/es not_active Application Discontinuation
-
2004
- 2004-08-20 NO NO20043472A patent/NO330223B1/no not_active IP Right Cessation
- 2004-08-27 BG BG108858A patent/BG66126B1/bg unknown
- 2004-08-27 HR HR20040781A patent/HRP20040781B8/xx not_active IP Right Cessation
-
2005
- 2005-09-16 HK HK05108134A patent/HK1076101A1/xx not_active IP Right Cessation
-
2007
- 2007-04-20 US US11/788,454 patent/US7279595B2/en not_active Expired - Fee Related
- 2007-07-12 CY CY20071100925T patent/CY1106721T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7279595B2 (en) | Process for the preparation of high purity perindopril | |
| KR850000302B1 (ko) | 옥타히드로-1h-인돌-2-카복실산 치환 아실유도체의 제조방법 | |
| US4716235A (en) | Process for preparing N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline | |
| NO174889B (no) | Analogifremgangsmåte for fremstilling av substituerte 4-(kinolin-2-yl-metoksy)fenyl-eddiksyrederivater | |
| AU2003206055A1 (en) | Process for the preparation of high purity perindopril and intermediates useful in the synthesis | |
| EP1272454B1 (fr) | Procede de synthese des esters de la n-[(s)-1-carboxybutyl]-(s)-alanine et application a la synthese du perindopril | |
| WO2009098251A1 (en) | NOVEL CYCLOALKANONE β-SUBSTITUTED ALANINE DERIVATIVES | |
| WO2005049568A1 (en) | A process for industrially viable preparation of (s,s,s) phenylmethyl-2-azabicyclo-[3.3.0]-octane-3-carboxylate tosylate | |
| EP1864973A1 (en) | Process for the preparation of perindopril and salts thereof | |
| US7960558B2 (en) | Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof | |
| JPS6145988B2 (sr) | ||
| JPS62132846A (ja) | ４−アミノブタン酸誘導体及びその製法 | |
| JPS60166670A (ja) | 新規な活性エステル化剤化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |